^
Association details:
| Biomarker: | CLDN18-ARHGAP fusion |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | CLDN18.2-targeted antibody-drug conjugate |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Histological subtypes and Specific Mutational Profiles: the forgotten ingredients for therapy development in Diffuse Gastric Cancer
Published date:
05/28/2021
Excerpt:
...the most promising treatment for DGC is a phase II study (NCT01197885), showing that patients with tumours presenting a CLDN18-ARHGAP fusion, benefit from treatment with anti-CLDN18.2 antibody
Trial ID:
